Rechtzeitig daran denken - Unerwünschte Arzneimittelwirkungen durch Interaktionen mit Antiinfektiva

Unerwünschte Arzneimittelwechselwirkungen werden häufig durch eine Beeinflussung der Enzyme der Arzneimittelbiotransformation (v.a. CYP3A4, CYP1A2) sowie von Transporterproteinen wie dem P-Glykoprotein in Darm und/oder Leber verursacht. Antibiotika wie Makrolide, Chinolone und Azolantimykotika, die Cytochrom-P-Enzyme (CYP-Enzyme) hemmen, bedingen meist ein höheres Nebenwirkungsrisiko. Der Grad der Hemmung kann dabei von genetischen Polymorphismen abhängen (z.B. Langsamacetylierung von Isoniazid). Betroffen sind vor allem Theophyllin (Rhythmusstörungen), orale Antikoagulanzien (Blutungen), Antikonvulsiva (Ataxie, Nystagmus), CSE-Hemmer (Myopathie, Rhabdomyolyse) oder H1-Antihistaminika (Herzrhythmusstörungen). Nach der Gabe von Enzyminduktoren wie Rifampicin oder Ritonavir kann die Therapie versagen, zum Beispiel im Sinne einer Transplantatabstoßung trotz einer Cyclosporintherapie. Die meisten Inhibitoren und Induktoren der Biotransformation beeinflussen jedoch auch das P-Glykoprotein. Auf diese Weise lassen sich auch Wechselwirkungen mit Arzneimitteln wie Digoxin oder Talinolol erklären, die nicht biotransformiert werden. Besonders stark reagieren Arzneimittel mit hohem „First-pass-Effekt” (z.B. Cyclosporin, HIV-Proteaseinhibitoren, CSE-Hemmer). Der verordnende Arzt muss bei einer notwendigen Komedikation daher immer Wechselwirkungen bedenken, die bestehende Therapie überprüfen und gegebenenfalls auf Alternativpräparate mit geringerem Interaktionsrisiko ausweichen.

Adverse drug reactions are often caused by influence on drug metabolizing enzymes (e.g. CYP3A4, CYP1A2) and drug efflux transporters (e.g. P-glycoprotein) in small intestine and/ or liver. Inhibition of CYP enzymes leads to higher risk of adverse effects as caused by macrolides, chinolones and azole antifungals. The extent of inhibition may be dependent on genetic polymorphisms (e.g. slow acetylation of isoniazid). Drugs which are mainly affected by drug interactions are theophylline (cardiac arrhythmias), oral anticoagulants (bleeding), anticonvulsants (ataxia, nystagmus), lipid lowering statins (myopathy, rhabdomyolysis) and H1-antihistaminics (cardiac arrhythmias). After enzyme induction with rifampicin or ritonavir, therapeutic failure may occur; e.g. cyclosporine (graft rejection), hormonal contraceptives („pill failure”). The most inhibitors and inducers of drug metabolism also influence P-glycoprotein. This is the rationale behind interactions which drugs that are not metabolized (e.g. digoxin, talinolol). The risk of adverse drug interaction is highest for drugs with extensive „first-pass” effect (e.g. cyclosporine, HIV protease inhibitors, statins). The prescribing physician should carefully consider possible interactions in planning drug therapy, re-evaluate the existing maintenance treatment and, if necessary, select an alternative drug with lower interaction potential.

adverse drug reaction - CYP enzymes - drug efflux transporters - theophylline - oral anticoagulants - anticonvulsants - statins - H1-antihistaminics

Literatur

• 1 Albengres E, Le H Louet, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance.  Drug Safety. 1998;  18 83-97
• 2 Balfour JA, Figgitt DP. Telithromycin.  Drugs. 2001;  61 815-829
• 3 Böger RH. Drug interactions of the statins and consequences for drug selection.  Int J Clin Pharmacol Ther. 2001;  39 369-382
• 4 Clark DW. Genetically determined variability in acetylation and oxidation. Therapeutic implications.  Drugs. 1985;  29 342-375
• 5 Cozza KL, Armstrong SC, Oesterheld JR. Concise guide to drug interaction principles for medical practice. Washington, London: Am Publ Inc 2003
• 6 De Sarro A, De Sarro G. Adverse reactions to fluoroquinolones. An overview on mechanistic aspects.  Curr Med Chem. 2001;  8 371-384
• 7 Deppermann KM, Lode H. Fluoroquinolones: Interaction profile during enteral absorption.  Drugs. 1993;  45 65-72
• 8 Desmond ID Padhi, Long P, Basha M, Anandan IV. Interaction between tacrolimus and erythromycin.  Ther Drug Monitor. 1997;  19 120-121
• 9 Greiner B, Eichelbaum M, Fritz P. et al. . The interaction of digoxin and rifampin: role of intestinal P-glycoprotein.  J Clin Invest. 1999;  104 147-153
• 10 Hebert MF, Fisher RM, Marsh CL. et al. . Effects of rifampin on tracrolimus pharmacokinetics in healthy volunteers.  J Clin Pharmacol. 1999;  39 91-96
• 11 Hurst M, Faulds D. Lopinavir.  Drugs. 2000;  60 1371-1379
• 12 Jetter A, Fuhr U. Medikamenteninteraktionen mit Chinolonen.  Pharm unserer Zeit. 2001;  30 429-434
• 13 Johne A, Brockmöller J, Bauer S. et al. . Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum).  Clin Pharmacol Ther. 1999;  66 338-345
• 14 Joshi N, Miller DQ. Doxycycline revisited.  Arch Intern Med. 1997;  157 1421-1428
• 15 Kitaichi K, Wang L, Takagi K. et al. . Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide.  Antimicrob Agents Chemother. 1999;  43 2697-2701
• 16 Köhler GI, Bode-Böger SM, Busse R. et al. . Drug-drug interactions in elderly patients. Relation to hospital admissions and multiple drug use.  Int J Clin Pharmacol Ther. 2000;  38 504-513
• 17 Laberge P, Martineau P. Clarithromycin-induced digoxin intoxication.  Ann Pharmacother. 1997;  31 999-1002
• 18 Lown KS, Mayo RR, Leichtman AB. et al. . Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.  Clin Pharmacol Ther. 1997;  62 248-260
• 19 Ouellet D, Hsu A, Quian J. et al. . Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers.  Br J Clin Pharmacol. 1998;  46 111-116
• 20 Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: An update.  Ann Pharmacother. 2000;  34 495-513
• 21 Self TH, Chrisman CR, Baciewicz AM, Bronze MS. Isoniazid drug and food interactions.  Am J Med Sci. 1999;  317 304-311
• 22 Strayhorn VA, Baciewicz AM, Self TH. Update on rifampin drug interactions, III.  Arch Intern Med. 1997;  157 2453-2458
• 23 Wakasugi H, Yano I, Ito T. et al. . Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein.  Clin Pharmacol Ther. 1998;  64 123-128
• 24 Westphal JF. Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin.  Br J Clin Pharmacol. 2000;  50 285-295
• 25 Westphal K, Weinbrenner A, Gießmann T. et al. . Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein.  Clin Pharmacol Ther. 2000;  68 6-12
• 26 Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophyllin metabolism by interferon.  Lancet. 1987;  2 939-941

Anschrift für die Verfasser